BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development Frederick, MD, May 2, 2024 – BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for [….]
Stem Cell Research Commission Awards MSCRF $14 Million to Accelerate Cures By Alex KeownMay 24, 2023 The Maryland Stem Cell Research Commission, a division of TEDCO, handed out more than [….]
Since its inception, MSCRF has invested over $170 million in over 500 projects to accelerate stem cell research, commercialization, and cures. With a 2023 fiscal year budget of $20.5M, MSCRF offers six funding opportunities to scientists and companies in the areas of clinical trials, discovery, commercialization, validation, launch, and post-doctoral fellowships. The fund has supported the creation and growth of many stem cell companies since launching the Accelerating Cures initiative in 2017.
2020 is over, but its impact on how employers recruit and hire talent will reverberate for years to come.
It’s an age-old thinking that the arts and sciences mix as well as oil and water, with artists being stereotyped as whimsical, quirky, and creative, and scientists as analytical, awkward, and calculating. Folks who use the acronym “STEAM” instead of “STEM”, which accounts for the addition of “Art”, are often met with criticism from folks who think that the arts are not technically rigorous enough to warrant inclusion.
RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer
Share Article
Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies
“What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies.” – Jon A. Rowley, PhD, founder and chief product officer, RoosterBio
FREDERICK, MD. (PRWEB) OCTOBER 05, 2021
RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) bioprocess systems for cell and gene therapy product developers, today announced Timothy M. Kelly, PhD, has joined the company as Chief Executive Officer and as a member of the Board of Directors. Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies in the U.S. and Europe.
“We are excited to welcome Tim to the RoosterBio team! Tim brings extensive leadership experience and a proven track record growing small companies into highly sustainable businesses. What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies,” said…
Biotech, Medtech, and pharma companies of all shapes, sizes, and focus areas are struggling to fill vacancies during a growth boom created by the pandemic and advancements in biomanufacturing, cell and gene therapy, and other bleeding-edge sectors. This ongoing boom has created an uber-competitive talent acquisition and retention environment that’s pushing hiring managers, talent leaders, and c-suite executives to evolve and adopt new talent hiring and retention strategies that give them a competitive hiring edge.
Maryland’s reputation as the destination state for biotech jobs and life science research continues to climb as new startups emerge across its biohealth cluster regions.
RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. RoosterGEM, abbreviated for Rooster Genetic Engineering Medium, complements RoosterBio’s hMSC cell engineering system to offer a new and streamlined path for discovery, preclinical, and applied product development research – faster than ever before.
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
